AOD-9604
A modified C-terminal fragment of human growth hormone designed for fat-loss effects without the broader anabolic action of full HGH.
Overview
AOD-9604 is a synthetic peptide corresponding to amino acids 176–191 of HGH, with an added tyrosine. It was originally developed as an anti-obesity drug targeting fat metabolism specifically — without affecting blood sugar or causing tissue overgrowth.
Benefits
- Promotes lipolysis in adipose tissue
- May inhibit lipogenesis
- No significant impact on insulin sensitivity
- Generally well-tolerated profile
Mechanism of Action
AOD-9604 mimics the lipolytic activity of HGH by stimulating fat breakdown in adipose tissue, without binding the full GH receptor cascade or producing IGF-1 elevation.
Dosage (informational only)
- Typical range
- 250–500 mcg per day
- Frequency
- Once daily, typically morning fasted
Available in oral and subcutaneous forms. Bioavailability favors injection.
Side Effects
- Generally well-tolerated
- Possible injection site reactions
- Mild fatigue in some users
Related peptides
A long-acting GLP-1 receptor agonist studied for its effects on appetite, satiety, and glucose regulation.
A dual GIP and GLP-1 receptor agonist with strong effects on appetite, glucose handling, and body composition.
An investigational triple agonist of GLP-1, GIP, and glucagon receptors producing some of the largest weight-loss results recorded in trials.